ArticleFrontiers in oncology2024

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.

Zachary D Wallen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.